{
    "clinical_study": {
        "@rank": "151375", 
        "arm_group": [
            {
                "arm_group_label": "LY2605541", 
                "arm_group_type": "Experimental", 
                "description": "LY2605541 administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Participants will continue to use mealtime insulin."
            }, 
            {
                "arm_group_label": "Insulin Glargine", 
                "arm_group_type": "Active Comparator", 
                "description": "Insulin glargine administered to participants with T1DM SQ QD for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Participants continue to use mealtime insulin."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "Control Arm.  Untreated healthy participants."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a two-period study of participants with type 1 diabetes mellitus (T1DM). In each\n      period, participants will receive once daily injections of stable dose LY2605541 or insulin\n      glargine for 28 to 35 days followed by procedures to look at how the body uses or stores\n      fats and sugars. Participants will continue to use meal time insulin throughout the study.\n      Healthy participants will also enroll in the study. They will not receive any study\n      medication."
        }, 
        "brief_title": "A Study of How LY2605541 and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Type 1 Diabetics:\n\n        - T1DM for more than 1 year with Hemoglobin A1c (HbA1c) of less than 9.5%\n\n        All Participants:\n\n          -  Otherwise fit and healthy\n\n          -  Non smoker\n\n        Exclusion Criteria:\n\n        Type 1 Diabetics:\n\n          -  Taking medication or supplements other than insulin to control diabetes\n\n          -  Suffered a hypoglycemic event in the last 12 months that required hospitalization or\n             have poor awareness of hypoglycemia\n\n        All Participants:\n\n        - Taking fibrates, thyroid replacement therapy, testosterone, beta blockers or systemic\n        corticosteroids"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01925989", 
            "org_study_id": "14872", 
            "secondary_id": "I2R-MC-BIDO"
        }, 
        "intervention": [
            {
                "arm_group_label": "LY2605541", 
                "description": "Administered SC", 
                "intervention_name": "LY2605541", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Insulin Glargine", 
                "description": "Administered SC", 
                "intervention_name": "Insulin Glargine", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 19, 2014", 
        "location": {
            "contact": {
                "last_name": "Eli Lilly"
            }, 
            "facility": {
                "address": {
                    "city": "Orlando", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32804"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Evaluation of the Effects of LY2605541 on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared With That of Insulin Glargine in Patients With Type 1 Diabetes Mellitus", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Sleep Respiratory Quotient (RQ) in Type 1 Diabetes Mellitus (T1DM)", 
            "safety_issue": "No", 
            "time_frame": "Day 30 post dose, overnight period (0000 to 0600 hours)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01925989"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Lipid Oxidation in T1DM and Healthy Participants", 
                "safety_issue": "No", 
                "time_frame": "Day  5 or Day 30 post dose, overnight period (0000 to 0600 hours)"
            }, 
            {
                "measure": "Basal Metabolic Rate for T1DM", 
                "safety_issue": "No", 
                "time_frame": "Day 30 post dose, overnight period (0000 to 0600 hours)"
            }, 
            {
                "measure": "Sleep Respiratory Quotient (RQ) of Untreated Healthy Participants", 
                "safety_issue": "No", 
                "time_frame": "Day 5, overnight period (0000 to 0600 hours)"
            }, 
            {
                "measure": "Total Number of Hours of Lipid Oxidation (RQ below 7.6) in T1DM and Healthy Participants", 
                "safety_issue": "No", 
                "time_frame": "23-hour period while in whole room calorimeter beginning on Day 4 or Day 29"
            }, 
            {
                "measure": "Change in RQ, Pre-breakfast to Post-breakfast Meal, in T1DM", 
                "safety_issue": "No", 
                "time_frame": "Day 30 post dose, 60 to 90 minutes after entering the whole room calorimeter"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}